Novo Nordisk acquiring Akero Therapeutics for $5.2bn
Denmark-based global pharma company Novo Nordisk is to acquire clinical stage company Akero Therapeutics for up to $5.2bn, filling a critical comorbidity gap within Novo Nordisk’s core therapeutic landscape. The deal adds potential first-in-class MASH (Metabolic Dysfunction-Associated Steatohepatitis, a severe form of fatty liver disease) therapy. This is Novo Nordisk’s largest R&D-focused acquisition to date, strategically aligning with its core…
Roche Expands Metabolic Portfolio with US$3.5bn acquisition of 89bio
Swiss multinational pharma and diagnostics giant Roche has signed a definitive agreement to acquire California-based biotech group 89bio in a deal worth up to US$3.5bn, planning to expand in cardiovascular, renal and metabolic diseases while diversifying beyond oncology and immunology. Roche will pay US$2.4bn upfront, and up to US$3.5bn if certain milestones are hit tied to commercial success / annual sales targets.…